PL427837A1 - Systemy do ciągłego obwodowego podawania latanoprostu dla obniżania ciśnienia śródgałkowego - Google Patents

Systemy do ciągłego obwodowego podawania latanoprostu dla obniżania ciśnienia śródgałkowego

Info

Publication number
PL427837A1
PL427837A1 PL427837A PL42783718A PL427837A1 PL 427837 A1 PL427837 A1 PL 427837A1 PL 427837 A PL427837 A PL 427837A PL 42783718 A PL42783718 A PL 42783718A PL 427837 A1 PL427837 A1 PL 427837A1
Authority
PL
Poland
Prior art keywords
latanoprost
systems
continuous peripheral
intraocular pressure
peripheral administration
Prior art date
Application number
PL427837A
Other languages
English (en)
Inventor
Paweł Grieb
Andrzej TYRAŁA
Marlena WEŁNIAK-KAMIŃSKA
Michał FIEDOROWICZ
Maciej ŚWIĄTKIEWICZ
Original Assignee
Gbj Pharma Spółka Z Ograniczoną Odpowiedzialnością
Instytut Medycyny Doświadczalnej I Klinicznej Im. M. Mossakowskiego Polskiej Akademii Nauk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gbj Pharma Spółka Z Ograniczoną Odpowiedzialnością, Instytut Medycyny Doświadczalnej I Klinicznej Im. M. Mossakowskiego Polskiej Akademii Nauk filed Critical Gbj Pharma Spółka Z Ograniczoną Odpowiedzialnością
Priority to PL427837A priority Critical patent/PL427837A1/pl
Priority to PCT/PL2019/050065 priority patent/WO2020106168A1/en
Publication of PL427837A1 publication Critical patent/PL427837A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Przedmiotem zgłoszenia jest forma farmaceutyczna latanoporostu, która charakteryzuje się tym, że jest systemem podawania leku przeznaczonym do podawania latanoprostu człowiekowi w sposób ciągły obwodowo, podskórnie lub przezskórnie. Ponadto, przedmiotem zgłoszenia jest też latanoporost oraz system zawierający latanoporost.
PL427837A 2018-11-22 2018-11-22 Systemy do ciągłego obwodowego podawania latanoprostu dla obniżania ciśnienia śródgałkowego PL427837A1 (pl)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL427837A PL427837A1 (pl) 2018-11-22 2018-11-22 Systemy do ciągłego obwodowego podawania latanoprostu dla obniżania ciśnienia śródgałkowego
PCT/PL2019/050065 WO2020106168A1 (en) 2018-11-22 2019-11-16 Systems for continuous systemic administration of latanoprost to reduce intraocular pressure

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL427837A PL427837A1 (pl) 2018-11-22 2018-11-22 Systemy do ciągłego obwodowego podawania latanoprostu dla obniżania ciśnienia śródgałkowego

Publications (1)

Publication Number Publication Date
PL427837A1 true PL427837A1 (pl) 2020-06-01

Family

ID=69156482

Family Applications (1)

Application Number Title Priority Date Filing Date
PL427837A PL427837A1 (pl) 2018-11-22 2018-11-22 Systemy do ciągłego obwodowego podawania latanoprostu dla obniżania ciśnienia śródgałkowego

Country Status (2)

Country Link
PL (1) PL427837A1 (pl)
WO (1) WO2020106168A1 (pl)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2228058A1 (en) * 2009-03-04 2010-09-15 Novagali Pharma S.A. Anionic oil-in-water emulsion containing prostaglandins and uses thereof
US20100247606A1 (en) * 2009-03-25 2010-09-30 Allergan, Inc. Intraocular sustained release drug delivery systems and methods for treating ocular conditions
PT2493474T (pt) * 2009-10-30 2019-11-26 Intratus Inc Métodos e composições para libertação prolongada de fármacos
US10220093B2 (en) * 2013-02-28 2019-03-05 Mira Pharma Corporation Long-acting semi-solid lipid formulations
NO2753788T3 (pl) * 2013-05-10 2018-06-16
JP6030168B2 (ja) * 2015-03-09 2016-11-24 テックフィールズ バイオケム カンパニー リミテッド 非常に高い皮膚浸透率を有するプロスタグランジン及び関連化合物の正荷電水溶性プロドラッグ

Also Published As

Publication number Publication date
WO2020106168A1 (en) 2020-05-28

Similar Documents

Publication Publication Date Title
MY189466A (en) Methods of modulating drug plasma levels using erythrohydroxybupropion
MX2019001103A (es) Sistema de suministro transdermico de donepezilo.
WO2015095772A3 (en) Formulations and methods for targeted ocular delivery of therapeutic agents
MX2016008138A (es) Sistema para el suministro transdermico de ingredientes activos.
TWD192266S (zh) 藥劑輸注裝置之部分
EP3513789A3 (en) Prophylactic and therapeutic agents for fgfr3 diseases
MX2016011333A (es) Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina.
PH12018502738A1 (en) Compositions, devices, and methods for the treatment of alcohol use disorder
MY199237A (en) Methods of treating ocular conditions
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
EA202090637A1 (ru) Способы применения дипивефрина
MX2016016400A (es) Formulaciones de oximetazolina estabilizadas y sus usos.
PL427837A1 (pl) Systemy do ciągłego obwodowego podawania latanoprostu dla obniżania ciśnienia śródgałkowego
TN2016000497A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2019004736A (es) Mini-tabletas de melatonina y metodos de fabricacion de las mismas.
MX2020006886A (es) Sistema para suministro de medicamento.
ZA202006986B (en) Dantrolene formulations and methods of their use
MX2022000468A (es) Metodos para aliviar la preocupacion asociada al pterigion sobre el aspecto del ojo.
EP4338751A3 (en) Medicament comprising combination of sepetaprost and rho-associated coiled-coil containing protein kinase inhibitor
MX2020005310A (es) Producto de combinacion que comprende dicicloplatino y metodo de preparacion y uso del mismo.
PH12016501347A1 (en) Filters for infusion sets
MX2021003274A (es) Combinacion farmaceutica para el tratamiento de cancer.
MX2020013385A (es) Metodos para modular los niveles de plasma de metabolitos de tetrabenazina utilizando bupropion.
SG10201908566YA (en) Dry eye therapeutic agent having as active ingredient nandrolone or ester thereof or methenolone or ester thereof
EA201990553A1 (ru) Применение придопидина для лечения ухудшения функциональной способности